AMRI, PerkinElmer to Collaborate on Drug Discovery
News Jun 18, 2015
The new AMRI center is part of the Buffalo Medical Innovation and Commercialization Hub (BMIC), a public-private pharmaceutical research and development initiative in Buffalo, New York. The Hub is a collaborative effort that involves SUNY Polytechnic Institute and the State of New York, AMRI, and other industry partners that provide services, platforms, and expertise needed to support drug development projects in academia and industry.
As a result of its collaboration with PerkinElmer, scientists at the BMIC hub will have access to AMRI's chemistry and biology expertise, and they will have access PerkinElmer's informatics technologies and high-content screening capabilities, as well as its cellular imaging and analytics instruments. PerkinElmer will also provide technical and informatics experts to facilitate technological and drug discovery innovations.
"We are pleased to have the opportunity to deliver the platforms, informatics technologies and services to AMRI for its new center of excellence for drug discovery and translational research," Jim Corbett, PerkinElmer's president, human health, said in a statement. "We look forward to supporting the BMIC's expansion by working closely with additional companies that establish lab facilities at this site."
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE